Loading stock data…
MCRB
$7.61+0.24 (+3.26%)
Market ClosedLast close May 1
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Seres Therapeutics, Inc. in the Healthcare sector is trading at $7.61. The stock is currently near its 52-week low of $6.53, remaining 47.5% below its 200-day moving average. Technical signals show neutral RSI of 33 and bearish MACD signal, explaining why MCRB maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 33) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.61
Potential Upside
331.3%
Whystock Fair Value$32.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$22.00+189.1%
Range$22.00 – $22.00
Fundamentals
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$80.91M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.19
Beta
Defensive asset. Lower volatility than the S&P 500.
0.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
194.41%
Volume
Today's trading volume
23,251
Recent News
Seres Therapeutics: Q4 Earnings Snapshot
CAMBRIDGE, Mass. AP) — Seres Therapeutics Inc. MCRB) on Thursday reported a loss of $15.3 million in its fourth quarter.
Sector Update: Health Care Stocks Rise Late Afternoon
Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index adding 0.8%
Seres to lay off staff, pause top program in latest reboot
The microbiome specialist, which for years has struggled to stay afloat, is cutting its staff by 30% and focusing resources on earlier, immunology-focused research.
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).